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ABSTRACT  27 
This study investigates the effects of drug-loaded nanofibers on the solubility of the poorly 28 
water-soluble drug, loratadine. Amorphous morphologies of electrospun loratadine nanofibers 29 
were prepared using a 3D-printed electrospinning setup. Polyvinylpyrrolidone was used as a 30 
carrier in the solvent preparation method. The prepared nanofibers were characterized by 31 
scanning electron microscopy, differential scanning calorimetry, X-ray diffraction analysis, 32 
Fourier transform infrared spectroscopy, solubility and in vitro dissolution studies with kinetic 33 
behavior evaluation. The scanning electron microscope images showed smooth nanofiber 34 
surfaces with a mean diameter of 372 nm. Moreover, both differential scanning calorimetry 35 
and X-ray diffraction analysis confirmed the amorphous state of the prepared nanofibers. FT-36 
IR results suggested that loratadine lost its original crystal structure by hydrogen bonding 37 
interactions. The fabricated nanofibrous drug samples demonstrated a remarkable 26-fold 38 
increase in solubility when compared to the pure drug in phosphate buffer at pH 7.4. 39 
Furthermore, dissolution studies showed that 66% of the drug from the nanofibrous mat was 40 
released in the first 10 min, which is significantly higher than the maximum of 4% drug 41 
release of the reference samples within the same time. Thus, Loratadine nanofibers can be 42 
considered as an alternative dosage form with improved physicochemical properties. 43 
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1. INTRODUCTION 47 
Loratadine (LOR) is a second-generation anti-histamine (H1) agent. It is frequently prescribed 48 
to treat allergic disorders without a central nervous system depressant effects (Simons, 2002). 49 
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LOR belongs to class II of the biopharmaceutical classification system that exhibits a poor 50 
water solubility (0.00303 mg mL-1) and high permeability (log P of 5) (Dagenais et al., 2009). 51 
From the chemical point of view, LOR contains pyridine nitrogen atom that is responsible for 52 
its pH-dependent solubility (Han et al., 2004). Its pKa value at 25 ºC has been reported as 53 
4.85–6.00 (Dagenais et al., 2009; Han et al., 2004; Omar et al., 2007). Related to the 54 
properties mentioned above, LOR shows low and variable bioavailability (Arya et al., 2012). 55 
Many possibilities have been applied to enhance the dissolution and solubility of LOR, which 56 
includes solid dispersion, inclusion with ß-cyclodextrin derivatives, micellar solubilization 57 
and self-microemulsifying drug systems (Frizon et al., 2013; Li et al., 2015; Nacsa et al., 58 
2009, 2008). 59 
In recent years, many efforts have been devoted to utilizing nanoparticle design for increasing 60 
the bioavailability of drugs. Preparation of LOR nanoparticles has been shown to enhance its 61 
dissolution and solubility (Alshweiat et al., 2018; Rodriguez Amado et al., 2017). The use of 62 
nanoparticles to produce LOR with increased hydrophilic properties shows promise and has 63 
opened the scope for new methods of preparation and administrations (Akhgari et al., 2016). 64 
Nanofibers, due to their architecture, are considered to be a sophisticated solution to the 65 
current inconveniences of drug delivery (Li et al., 2015). Drugs based on nanofibers show 66 
faster dissolution kinetics than their micron-sized counterparts, as nanofibers have a 67 
significantly higher surface area to volume ratio (Jiang et al., 2004). 68 
Among different method of preparation, electrospinning is considered as the most efficient 69 
process in nanofiber production. This process has been recognized as simple and versatile to 70 
produce nanofibers with low cost (Huang et al., 2003). Radacsi et al. (Radacsi et al., 2018) 71 
reported the benefits of electrospinning on scaling up to high yield. This feature makes 72 
electrospinning attractive for the industry over the electrospray technique. Both methods are 73 
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based on electrohydrodynamic atomization and have been demonstrated to improve the 74 
physicochemical properties of drug particles (Ambrus et al., 2013; Radacsi et al., 2019). 75 
The poor water solubility of the active pharmaceutical ingredients (APIs) and candidates is 76 
one of the major challenges of the pharmaceutical industry (Craig, 2002). The delivery of 77 
these agents is associated with poor bioavailability (Amidon et al., 1995). As a novel drug 78 
manufacturing method, electrospinning is mainly focused on enhancing the dissolution of 79 
poorly water-soluble drugs. The enhanced dissolution of drugs in the nanofibers are related to 80 
presence of the amorphous state, high specific surface area, increased wettability and 81 
solubility, and lower precipitation (Nagy et al., 2012). This offers alternative drug delivery 82 
methods, e.g. the electrospun drug films can be used for transdermal delivery, or it can 83 
dissolve in the oral cavity (e.g. sublingual or buccal administration), which can be 84 
advantageous for patients that cannot swallow (Shahriar et al., 2019). Furthermore, the 85 
advanced bioavailability also reduces the side-effects of the drugs (Badawy et al., 1996). 86 
Recently, academic and industrial efforts have concentrated on enhancing the dissolution of 87 
the poorly water-soluble pharmaceutical agents by electrospinning technology. The 88 
fabrication of itraconazole nanofibers using the co-polymer PVPVA64 as a carrier was done 89 
by novel high-speed electrospinning method (Nagy et al., 2015). The produced amorphous 90 
nanofibers showed rapid dissolution, 90% of the drug was dissolved within 10 min. The high-91 
speed electrospinning method has a significantly higher production rate than the conventional 92 
electrispinning techniques, making it attractive for industrial pharmaceutical manufacturing. 93 
In another study, electrospinning of itraconazole was performed with 94 
hydroxypropylmethylcellulose as a carrier polymer (Verreck et al., 2003). The authors 95 
highlighted the amorphous structure and the rapid and complete dissolution of the API, 96 
itraconazole, from the prepared nanofibers.  97 
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Electrospinning has been utilized in poorly water-soluble analgesics. Ketoprofen showed a 98 
significant dissolution from the prepared nanofibers with PVP K30 as a drug carrier and 99 
filament-forming a polymer. The complete drug release was achieved within just 30 min. 100 
However, the pure drug showed approximately 5% release after 2 h (Yu et al., 2010). 101 
Moreover, niflumic acid loaded nanofibers into PVP (MW = 1,300,000) were incorporated 102 
into capsules. The formulations showed a drug release of 69-91% after 15 min (Radacsi et al., 103 
2019). The high drug release from nanofibers was also achieved in acetaminophen. Yu et al 104 
(Yu et al., 2010) found that 93.8% of poorly water-soluble acetaminophen was released in the 105 
first 2 min from the PVP (Mw=360,000) drug-loaded nanofibers. Furthermore, ibuprofen has 106 
been fabricated into nanofibers (Potrč et al., 2015). The nanofibers released 100% of the 107 
ibuprofen in 4 h.  108 
To prepare nanofibers of the poorly water-soluble plant sterol. Paaver and co-workers (Paaver 109 
et al., 2016) fabricated β-sitosterol loaded chitosan nanofibers. The prepared nanofibers 110 
exhibited freely water-soluble properties with a very short lag-time in releasing the β-111 
sitosterol. In a study by Li et al (Li et al., 2013), rapid and improved dissolution rates have 112 
been achieved for caffeine and riboflavin nanofibers, using polyvinyl alcohol polymer as 113 
filament-forming polymer and drug carrier. The nanofibers showed 100% and 40% release of 114 
caffeine and riboflavin, respectively within 60 s.  115 
In comparison to the conventional processes of solid dispersion fabrication, electrospinning 116 
can produce nanofibers with enhanced dissolution compared to film casting (Potrč et al., 117 
2015) freeze-drying, vacuum drying, and heating drying (Yu et al., 2010). 118 
Many studies discussed the effects of the material and process parameters of electrospinning 119 
on the release of poorly water-soluble drugs from the nanofibers. These parameters include; 120 
drug characteristics (Potrč et al., 2015), polymer type (Baskakova et al., 2016), drug and 121 
polymer ratios (Brewster et al., 2004), solvents type and ratios (Paaver et al., 2016), in 122 
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addition to the electrospinning parameters of voltage (Verreck et al., 2003), and the distance 123 
between the collector and the spinneret (Radacsi et al., 2019). 124 
The material properties affect the properties of the solutions, such as viscosity and surface 125 
tension thus morphology and size of the electrospun nanofibers (Fong et al., 1999). In general, 126 
concentration is a critical factor determining the solution viscosity, whereas polymer and 127 
solvent affect the value of the surface tension (Yang et al., 2004). Moreover, adjusting the 128 
process parameters has significant effects on controlling the final structure of the electrospun 129 
fibers (Ryu et al., 2003). 130 
Polyvinylpyrrolidone (PVP) is a widely used polymer for preparing electrospun fibers. It 131 
shows low toxicity, high biocompatibility and excellent solubility in most organic solvents 132 
(Chuangchote et al., 2009). Furthermore, PVP with the Mw 1,300,000 g mol-1 has been the 133 
most thoroughly investigated in reported studies related to electrospinning with PVP (Li and 134 
Xia, 2003; Nuansing et al., 2006). 135 
In the present study, a low-cost 3D-printed electrospinning setup is investigated as a new 136 
formulation method for the fabrication of nanostructured LOR. From the production point of 137 
view, this study considered the first application of a setup prepared by fused deposition 138 
modelling printing method with 3D-printed components (Huang and Radacsi, 2019). 139 
Concerning the pharmaceutical goal, this study aimed to produce nanofiber with enhanced 140 
dissolution and high drug loading of the poorly water-soluble LOR. These properties enable 141 
the incorporation of the nanofibers into different dosage form such as oral, buccal, topical, 142 
and transdermal with improved bioavailability. The size and morphology of the produced 143 
LOR-PVP nanofibers were characterized by scanning electron microscopy. The structure of 144 
the products was investigated using differential scanning calorimetry, X-ray powder 145 
diffraction and Fourier transform infrared. The solubility and in vitro release of the selected 146 
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product was studied in a phosphate buffer solution at pH 7.4 and was compared with the 147 
corresponding physical mixture and a prepared reference sample. 148 
 149 
2. Experimental 150 
2.1 Materials 151 
Loratadine (LOR) was purchased from Teva Ltd. (Budapest, Hungary). Polyvinylpyrrolidone 152 
(PVP; Mw 1,300,000 g mol-1) was purchased from Alfa Aesar, UK. 99.99% purity ethanol 153 
was obtained from Fisher Scientific, UK. 154 
 155 
2.2. Solution preparation and electrospinning 156 
LOR: PVP at 1:1 ratio was used to prepare the electrospinning samples containing PVP as a 157 
carrier and ethanol as a solvent system. 0.77 g LOR was mixed with 0.77 g PVP, and this 158 
powder mixture was dissolved in 50 mL ethanol. The electrical conductivity of the solution 159 
was 2 μS cm-1. This solution was sucked into a 60 mL syringe (BD plastics). The nanofibers 160 
were produced in a 3D-printed electrospinning setup (Figure 1). The details of the 3D printing 161 
process and the files of the electrospinning setup can be found in another work (Huang and 162 
Radacsi, 2019). A 20G needle was applied at the tip of the syringe, and it was placed into the 163 
syringe pump (Cole-Parmer, USA). The LOR solution was injected into the 3D-printed 164 
chamber through a Teflon tube using the automatic pump with a pumping speed of                        165 
15 μL min-1. The Teflon tube (inner diameter 0.8 mm) was connected to a blunt 20G needle 166 
that was placed inside the 3D-printed setup and was covered by a safety cap to prevent 167 
electric shock. The blunt nozzle was charged by a +35 kV DC high-voltage power supply 168 
(Information Unlimited, Amherst, USA) at its maximum voltage. The working distance (WD) 169 
between the spinneret and the fiber collector was set to either 65 or 95 mm (95 mm was the 170 
maximum distance possible in the setup without using extension parts). The fibers were 171 
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collected on an 80 mm wide grounded stainless steel drum, which was rotating with a speed 172 
of 100 rpm. A constant stream of air (5.2 ms-1) was supplied into the chamber opposing the 173 
direction of the electrospun fibers, in order to increase the evaporation rate of the solvent from 174 
the electrospun jet and the fibers as they travelled across the chamber. Two different working 175 
distances between the injection nozzle and the collection drum were tested in the experiments, 176 
and all the other parameters were fixed. The experiments were performed at room temperature 177 
at the relative humidity of 42-49%. Each run lasted for 15 minutes.  178 
 179 
Figure 1. Schematic illustration of the 3D-printed modular electrospinning setup. 180 
 181 
2.3 Preparation of the reference samples  182 
The reference samples, physical mixture (PM) and the solvent evaporated sample (SE), were 183 
prepared by two different methods to control the effect of polymer and re-crystallization 184 
procedure on the physicochemical properties of LOR. In the first method the physical mixture 185 
(PM) was prepared by Turbula mixer System (Schatz; Willy A. Bachofen AG 186 
Maschinenfabrik, Basel, Switzerland) of LOR and PVP with 1:1 ratio at 50 rpm for 10 min 187 
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(PM). The second method involved the evaporative re-crystallization of the previously mixed 188 
PM which was dissolved in 100 mL ethanol. The solvent was evaporated at 25 ºC. The 189 
preparation methods of the nanofibers and reference samples are summarized in Table 1. 190 
 191 
Table 1. Composition and method of preparation of loratadine nanofibers and reference samples. 
Sample  Abbreviation  LOR (g) PVP (g) Method of preparation  
Raw loratadine  LOR - - - 
Physical mixture PM (1:1) 5  5 Turbula mixer  
(for 10 mins) 
Re-crystallized PM from 
100 mL ethanol solution 
SE (1:1) 5 5 Solvent evaporation  
(at 25 °C) 
Loratadine-Nanofiber 
Experiment 1 
LOR-NF1 5 5 Electrospinning method 
(WD = 65 mm) 
Loratadine-Nanofiber 
Experiment 2 
LOR-NF2 5 5 Electrospinning method 
(WD = 95 mm) 
 192 
2.4 Scanning electron microscopy (SEM) 193 
The morphological appearance of the electrospun fibers was investigated by scanning electron 194 
microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) at 10 kV. The 195 
samples were coated with gold-palladium (90 seconds) by a sputter coater (Bio-Rad SC 502, 196 
VG Microtech, Uckfield, UK). One hundred nanofibers were selected from each SEM image, 197 
and the mean fiber diameter was measured by ImageJ 1.44p software (NIH, USA).  198 
 199 
2.5 Differential scanning calorimetry (DSC) 200 
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Differential scanning calorimeter (Mettler Toledo TG 821e DSC; Mettler Inc., 201 
Schwerzenbach, Switzerland) was used to measure the thermal response of the samples. 202 
Approximately 3 – 5 mg of the sample was precisely weighed into DSC sample pans, which 203 
were hermetically sealed, then the lid was pierced. Each sample was measured in the 204 
temperature interval of 25 °C – 300 °C at a heating rate of 5 °C min-1 under constant argon 205 
flow of 150 mL min-1.  206 
 207 
2.6 Fourier-transform infrared spectroscopy (FT-IR) 208 
FTIR spectrum of each sample was obtained by using Fourier transform infrared spectroscopy 209 
(Thermo Nicolet AVATAR 330, USA) equipped with GRAMS/AI Version 7.00 software. 210 
The samples were ground with 150 mg dry KBr in a mortar and pestle, then compressed into a 211 
disc at 10 t pressure. The discs were scanned 128 times at a resolution of 4 cm-1 over                        212 
4000-400 cm-1 wavenumber region. 213 
 214 
2.7 X-ray powder diffraction (XRPD) 215 
The crystalline phase of LOR, PM, SE, and LOR-NFs was characterized using an X-ray 216 
powder diffraction (XRPD) BRUKER D8 Advance X-ray diffractometer (Bruker AXS 217 
GmbH, Karlsruhe, Germany) with Cu K λI radiation (λ = 1.5406 Å) and a VÅNTEC-1 218 
detector. The powder samples were scanned at 40 kV and 40 mA, with an angular range 3° to 219 
40° 2θ, at a step time of 0.1 s and a step size of 0.02°r. 220 
Eva software was used to separate the crystal and related amorphous peaks. Thus, the 221 
software calculated the values of the integrated intensities of the amorphous and crystalline 222 
contribution and the crystalline-only contribution. The crystallinity index values (Xc) of the 223 
samples were calculated based on the following equation: 224 
 225 
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𝑋𝑐 = 𝐴௖௥௬௦௧௔௟௟௜௡௘ 𝐴௖௥௬௦௧௔௟௟௜௡௘ +  𝐴௔௠௢௥௣௛௢௨௦⁄        (1) 226 
 227 
2.8 Dissolution studies 228 
Modified paddle method (USP dissolution apparatus, type II Pharma Test, Hainburg, 229 
Germany) was used to determine the rates of dissolution of LOR, PM, SE, and LOR-NFs. 230 
Samples containing 1.11 mg of loratadine were placed in 100 mL of phosphate buffer solution 231 
at pH 7.4. The paddles were rotated at 100 rpm at 37 °C. At predetermined time 5 m aliquot 232 
was withdrawn, filtered and measured for loratadine content using UV spectrophotometry 233 
(Unicam UV/VIS Spectrophotometer, Cambridge, UK) at max 248nm. The sampling was 234 
performed for 120 min. 235 
 236 
2.9 Model-independent kinetics of dissolution profiles 237 
The dissolution behavior of the samples was characterized by calculating the dissolution 238 
efficiency (DE) at different time points. The DE represents the percentage of the ratio of the 239 
area up to time t divided by the area that described 100% dissolution at the same time (Khan, 240 
1975): 241 
%𝐷𝐸 = (∫ 𝑦 𝑋௧଴  𝑑𝑡) (𝑦ଵ଴଴ 𝑋 𝑡) × 100%ൗ         (2) 242 
The relative dissolution (RD) at 60 min was calculated relative to LOR by using the following 243 
formula: 244 
𝑅𝐷60 𝑚𝑖𝑛 = % 𝐷𝐸60 𝑚𝑖𝑛 % 𝐷𝐸60 𝑚𝑖𝑛⁄         (3) 245 
 246 
The area under the curve (AUC) was calculated by the trapezoidal method. AUC represents 247 
the sum of all trapezia: 248 
𝐴𝑈𝐶 = ∑ [(𝑡ଵ − 𝑡௜ିଵ)(𝑦௜ିଵ + 𝑦௜)௜ୀ௡௜ୀଵ 2]⁄         (4) 249 
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Where ti represents the time point and yi is the percentage of sample dissolved at time ti. The 250 
mean dissolution time (MDT) was calculated using the following formula (Costa, P., & Lobo, 251 
2001) 252 
𝑀𝐷𝑇 = ∑ 𝑡𝑚𝑖𝑑∆ 𝑀𝑛𝑖−1 ∑ ∆ 𝑀𝑛𝑖−1⁄          (5) 253 
Where i is the dissolution sample number, n is the number of dissolution times, tmid is the time 254 
at the midpoint between times ti and ti−1, and ΔM is the amount of the dissolved drug (mg) 255 
between times ti and ti−1. 256 
 257 
3. Results and discussion  258 
3.1 Morphology and diameter of the LOR-NFs 259 
Smooth LOR nanofibers without the presence of beads were obtained from the 260 
electrospinning of PVP alcohol solutions (Figure 2c and 2d). The collection distance had a 261 
significant effect on the diameter of the prepared nanofibers. 95 mm collection distance 262 
resulted in the formation of smooth nanofibers with small diameter (372 ± 181 nm). The low 263 
diameter indicates that the nanofibers were stretched enough and sufficiently dried before 264 
deposition on the collector. On the other hand, large diameter and fused fibers were obtained 265 
at the shorter collection distance (65 mm). The nanofibers in this experiment (LOR-NF1) 266 
appeared to not well featured and fused as an indication of the incomplete drying. 267 
Furthermore, the protruded fiber shows a large diameter (948 ± 234 nm) and plasticized shape 268 
as another indication of not complete drying. The PM showed the characteristic crystal of 269 
LOR that showed a crystal size larger than 2 μm (Figure 2a). The SE showed irregular shapes 270 
of LOR crystal, both short rod and prisms were present. Moreover, the rod shape crystals 271 
exhibited a diameter of 562.7 ± 379 nm. The image of SE (Figure 2b) also showed the 272 
aggregation and variety of distribution of LOR within the matrix of PVP polymer. 273 
 274 
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Figure 2. Scanning electron microscopy images of the (a) physical mixture; (b) sample 275 
prepared by solvent evaporation; (c) electrospun nanofibers using the working distance of 65 276 
mm (LOR-NF1); (d) electrospun nanofibers using the working distance of 95 mm (LOR-277 
NF2). The SEM image (d) shows separated, more uniform and smaller diameter nanofibers 278 
compared to (c).  279 
 280 
3.2 Structural analysis (DSC, XRPD, and FT-IR) 281 
The DSC thermogram of LOR exhibited a sharp endothermic peak at 136.65 °C 282 
corresponding to its melting point. The filament-forming matrix polymer PVP showed a broad 283 
endotherm between 50 and 100 °C with a peak at 90 °C related to dehydration. The PM and 284 
SE showed the characteristic peak of LOR indicating the presence of LOR in its crystalline 285 
status. However, these endothermic peaks showed a lower intensity compared to pure LOR 286 
due to the reduction of crystallinity either by the dilution effect (PM) and/or the preparation 287 
method (SE). DSC of LOR-NFs exhibited a broad peak at temperatures lower than 60 °C, 288 
primarily caused by the thermal effect of moisture evaporation and also the glass transition. 289 
Moreover, the endothermic peak of LOR has disappeared in the prepared NFs indicating that 290 
LOR was no longer present as a crystalline, but had been converted into an amorphous state 291 
(Figure 3) (Akhgari et al., 2016).  292 
 293 
Figure 3. DSC thermograms of the raw materials, reference samples and the prepared 294 
nanofibers. The reference samples (PM and SE) show the melting point of LOR while 295 
electrospun nanofibers represent the amorphous nature of the LOR. 296 
 297 
The X-ray diffraction patterns of the LOR, PVP, PM, LOR-NF1, and LOR-NF2 are presented 298 
in Figure 4. LOR showed numerous peaks between 3-30 of the 2-θ scale indicated that LOR is 299 
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present as a crystalline material. PVP showed two broad halo peaks specified to amorphous 300 
status. PM showed the same characteristic peaks of pure LOR while SE showed the lower 301 
intensity of LOR peaks in addition to the absence of many peaks due to the reduction of the 302 
crystallinity. LOR-NF1 and LOR-NF2 showed complete disappearance of LOR characteristic 303 
peaks. However, the two halo peaks of PVP were observed in the electrospun fibers at the 304 
same position and showed the same shape. 305 
 306 
 307 
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Figure 4. XRPD diffractograms of the raw materials, reference samples and the prepared 308 
nanofibers. The electrospun nanofiber samples were amorphous, while the reference samples 309 
(PM and SE) show the crystalline peaks of LOR. 310 
 311 
The crystallinity index (XC) values were calculated to reveal the changes in the degree of 312 
crystallinity of the LOR nanofibers and SE with respect to the PM (Gombás et al., 2002). The 313 
crystallinity indices from XRPD and DSC further suggest the amorphous state of the prepared 314 
LOR-NFs (Table 2). The nominal values of XC obtained from DSC curves were different from 315 
that found by XRPD measurements for the samples. The differences in the measurements 316 
were expected because of using comparative methods to obtain data rather than absolute ones 317 
(Tserki et al., 2006). In the case of XRPD, the XRPD patterns were separated by the software 318 
into crystalline and amorphous peaks, and the degree of crystallinity was estimated based on 319 
equation (1). In spite of the qualitative analysis of the amorphous peaks by this method, the 320 
same procedure was applied to all samples in order to get comparable values. On the other 321 
hand, the values obtained by DSC were based on the heat of fusion. Both methods represented 322 
the variation of crystallinity between the prepared samples. 323 
 324 
Table 2. The calculated crystallinity index (Xc) of the reference samples and the 
prepared nanofibers after DSC and XRPD measurements compared to LOR. 
Sample  Crystallinity index (%) 
XRPD DSC 
SE 32.71 47.29 
LOR-NF1 30.28 0.93 
LOR-NF2 9.79 0.93 
 325 
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FT-IR analysis was performed to check the compatibility and interactions between LOR and 326 
the nanofiber matrix (Figure 5). The FTIR bands that are characteristic to LOR are located at 327 
997 cm−1 for aryl C-Cl stretching and 1,227cm−1 for -C-N stretching of aryl N. In addition to 328 
bands at 1560 and 1703 cm−1 corresponded to C-O bonds of the amide or ester groups. Bands 329 
from 3000 to 2850 cm−1 correspond to the C-H bond (Alshweiat et al., 2018). On the other 330 
hand, PVP showed its characteristic bands at 3448.3 cm−1 due to O-H stretching vibrations, 331 
2924.4 cm−1 related to asymmetric stretching of CH2, 1652.3 cm−1 for C=O stretching and a 332 
broad peak at 1289.4 cm−1 due to C-N stretching vibrations (Sriyanti et al., 2018). The FTIR 333 
spectra of the physical mixture and the reference sample showed no obvious shift of the peaks 334 
of the functional groups corresponding for hydrogen bonding. However, LOR-NF samples 335 
showed shifted peaks of LOR and PVP. The main effects were observed in the O-H and C=O 336 
regions. The hydroxyl peak of PVP at 3448.3 cm−1 shifted to 3512 cm−1 and the C=O 337 
stretching peaks at 1652.3 cm−1 shifted to 1666.5 cm−1. The band of LOR shifted from 1702.8 338 
to 1666.5 overlapping with the shifted peak of PVP. The peak shift of carbonyl stretching was 339 
thought to be a result of hydrogen bond intermolecular interaction between LOR and PVP 340 
(Zhao et al., 2017). Since the FTIR results showed only hydrogen bonding, but no covalent 341 
bonding, LOR and PVP as nanofibers are indicated to be compatible with each other (Frizon 342 
et al., 2013; John et al., 2002). 343 
 344 
Figure 5. FT-IR spectra of the raw materials, reference samples and the prepared electrospun 345 
nanofibers. The electrospun nanofiber samples and SE sample show an intermolecular 346 
interaction between LOR and PVP via hydrogen bond formation. 347 
 348 
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According to the aforementioned characteristics of the LOR-NFs, only the LOR-NF2 showed 349 
the complete separation of the fibers and nanofibers with small diameters. Therefore, it was 350 
selected for further solubility and dissolution studies. 351 
 352 
3.3 Solubility and Dissolution studies 353 
LOR-NF2 showed a 26.2-fold increase of LOR solubility compared to the pure drug in 354 
phosphate buffer solution, pH 7.4. The solubility of LOR-NF2 was 13.1 ± 0.26 µg mL-1 355 
compared to 0.50 ± 0.11 μg mL-1 for LOR at 25 °C (Table 3). The dissolution behaviors of the 356 
samples are shown in Figure 6. LOR-NF2 showed the highest release rate, more than 66% of 357 
the drug was released in the first 10 min compared to less than 0.5% of the pure LOR. SE 358 
samples also showed higher dissolution than LOR because of their contact with the 359 
hydrophilic polymer. However, the PM exhibited a release behavior similar to LOR. The 360 
improvement in the dissolution of LOR from the electrospun fibers was attributed to the 361 
presence of LOR in the amorphous state. Loratadine has been reported to have higher kinetic 362 
energy in the amorphous state, hence higher dissolution than its crystalline state. Moreover, 363 
the three-dimensional structure of the electrospun fiber can offer a larger surface area, 364 
therefore, water can diffuse more efficiently into the polymer to dissolve the drug. The 365 
dissolution efficiency of LOR-NF2 was enhanced at all selected time points, as well as RD 366 
value. The mean dissolution time of LOR-NF2 was decreased. These results confirmed that 367 
the dissolution became fast due to the amorphous state of the drug in the nanofibers, presence 368 
of the additives, and reduction of the particle size Table (4). 369 
 370 
Table 3. Solubility (µg mL-1) of LOR and the prepared samples in phosphate 
buffer at pH 7.4 at a temperature of 25 °C. 
Sample  Solubility (µg mL-1) 
 18
LOR 0.50 ± 0.11 
PM 6.45 ± 0.06 
SE 7.58 ± 0.38 
LOR-NF2 13.1 ± 0.11 
 371 
Figure 6. Dissolution behavior of LOR, reference samples and the prepared electrospun 372 
nanofiber with working distance 6.5 mm in phosphate buffer solution, pH 7.4. The nanofiber-373 
based sample has improved dissolution kinetics and higher dissolution rates than the raw LOR 374 
or the reference samples (PM and SE). 375 
 
Table 4. Dissolution efficiency (DE) at different time points, mean dissolution time 
(MDT), and relative dissolution (RD), with respect to the raw LOR at 60 min of the 
samples.  
Sample %DE30 %DE60 %DE120 MDT RD60 
LOR 1.47 3.73 4.60 36.69 - 
PM 0.69 1.46 3.45 53.63 0.39 
SE 5.64 7.06 8.54 13.28 1.89 
LOR-NF2 61.2 70.89 75.52 5.87 19.0 
 376 
4. Conclusion  377 
This study demonstrated home setup, low-cost, 3D-printed, electrospinning sources for 378 
generation of nanofibers using a rotating metal drum as a collector. Nanofibers of LOR were 379 
prepared in the hydrophilic PVP polymer and compared to the corresponding physical 380 
mixture and conventional reference sample, that was prepared by the solvent evaporation 381 
method. The distance between the nozzle and collecting drum was an influential process-382 
parameter; it affected the possibility of preparing separated nanofibers. Moreover, it affected 383 
the diameters of the nanofibers. 65 mm distance was optimum to produce separated 384 
nanofibers with diameters of 372 nm. The prepared nanofibers displayed an amorphous status 385 
of LOR, and the spectroscopic studies indicated interactions between the drug and polymer. 386 
As a result of the formation of the amorphous nanofibers, the solubility and dissolution of 387 
 19
LOR were enhanced. Solubility studies showed a marked increase in release rate compared to 388 
the pure drug. LOR-NF2 showed a 26.2-fold increase in the solubility of LOR as compared to 389 
the pure drug in phosphate buffer solution, pH 7.4. Moreover, more than 66% of the drug was 390 
released in the first 10 min compared to less than 4% drug release from the conventional 391 
reference sample (SE). Therefore, faster and higher dissolution was achieved for the poorly 392 
water-soluble LOR by fabrication of electrospun nanofibers. The improved dissolution could 393 
enable the designing of new alternative loratadine formulations, including buccal, 394 
transdermal, and topical dosage forms.  395 
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